Surface-enhanced Raman scattering (SERS) spectroscopy of single-cell suspensions obtained from fresh specimens of breast cancer tissue and normal breast tissue by mechanical enzymatic digestion was obtained and analysed, which is different from most Raman studies using breast cancer cell lines. Random forest classification was implemented to develop effective diagnostic algorithms for the classification of SERS of different typed cells. We first examined the SERS spectra of the primary breast cancer single cell and normal epithelial single cell obtained by flow sorting cytometry due to their biomarkers of CD326+/CD45-. Comparison analyses on their SERS spectra disclose that the nucleic acid and protein levels of the primary breast cancer single cell are higher than those of the normal epithelial single cell, while the lipids are at a relatively lower level. An important finding is that the cholesterol, palmitic acid, and sphingomyelin in the cancer cell profiles exhibit stronger than those of normal cells, while the glycans are at a relatively lower level. Furthermore, the standard deviation (SD) of the normal epithelial single cell is larger than that of the breast cancer cell, and the SD of the primary breast cancer single cell is more obvious than that of the normal epithelial cells. In addition, the prospective application of an algorithm to the dataset results in an accuracy of 78.2%, a precision of 75.5%, and a recall of 66.7%. The breast cancer diagnostic model laid a solid foundation for judgment of breast-conserving surgical margins and early diagnosis of breast cancer.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.saa.2020.118364 | DOI Listing |
Biomol Biomed
January 2025
Necmettin Erbakan University, Meram Faculty of Medicine, Department of Medical Oncology, Konya, Turkey.
The cysteine-rich epidermal growth factor ligand domain 2 protein (CRELD2) is associated with pathways that regulate epithelial-to-mesenchymal transition, a critical process driving cancer metastasis. This study aimed to determine the prognostic value of CRELD2 status on survival outcomes in triple-negative breast cancer (TNBC). Seventy patients were included in the study.
View Article and Find Full Text PDFClin Cancer Res
January 2025
Mater Research Institute - University of Queensland, Woolloongabba, Qld, Australia.
Purpose: Receptor CUB-domain containing- protein 1 (CDCP1) was evaluated as a target for detection and treatment of breast cancer.
Experimental Design: CDCP1 expression was assessed immunohistochemically in tumors from 423 patients (119 triple-negative breast cancer (TNBC); 75 HER2+; 229 ER+/HER2- including 228 primary tumors, 229 lymph node and 47 distant metastases). Cell cytotoxicity induced in vitro by a CDCP1-targeting antibody-drug conjugate (ADC), consisting of the human/mouse chimeric antibody ch10D7 and the microtubule disruptor monomethyl auristatin E (MMAE), was quantified, including in combination with HER2-targeting ADC T-DM1.
Clin Cancer Res
January 2025
Massachusetts General Hospital Cancer Center, Boston, MA, United States.
Background: Race/ethnicity may affect outcomes in metastatic breast cancer (MBC) due to biological and social determinants. We evaluated the impact of race/ethnicity on clinical, socioeconomic, and genomic characteristics, clinical trial participation, and receipt of genotype-matched therapy among patients with MBC.
Methods: A retrospective study of patients with MBC who underwent cell-free DNA testing (cfDNA, Guardant360â, 74 gene panel) between 11/2016 and 11/2020 was conducted.
Endocrine
January 2025
Department of Zoology, Institute of Science, Banaras Hindu University, Varanasi, Uttar Pradesh, India.
The word "cancer" evokes myriad emotions, ranging from fear and despair to hope and determination. Cancer is aptly defined as a complex and multifaceted group of diseases that has unapologetically led to the loss of countless lives and affected innumerable families across the globe. The battle with cancer is not only a physical battle, but also an emotional, as well as a psychological skirmish for patients and for their loved ones.
View Article and Find Full Text PDFBreast Cancer Res Treat
January 2025
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
Purpose: Individuals with metastatic breast cancer (MBC) may live with their disease for many years. We initiated the Johns Hopkins Hope at Hopkins Clinic to assess the needs and optimize the care of these patients.
Patients And Methods: Patients with MBC who agreed to participate in the Clinic in addition to usual care completed patient-reported outcome (PRO) surveys.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!